GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc.(Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019 before the market open and host a conference call on Wednesday, August 14, 2019.
|Conference Call Details|
|Date:||Wednesday, August 14|
|Time:||8:30 am Eastern Time|
Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimmune, please visit www.altimmune.com.
|Will Brown||Ashley R. Robinson|
|Chief Financial Officer||LifeSci Advisors, LLC|
Source: Altimmune, Inc.